Best Niche Antibody-based Biologics

PD-1 (Fc-Fusion)

PD-1 (Fc-Fusion)

Part No. P7099F
Regular price
$ 499.00
Sale price
$ 499.00
Regular price
Out of Stock
Unit price
per 

The extracellular domain of PD-1 (programmed cell death protein 1) contains a single IgV domain. Signaling mediated through (PD-1) can lead to a number of immunological outcomes. These include inhibition of cell death of regulatory T cells, activation of the cell death of the antigen-specific T cells. Combination of these effects can lead to self-tolerance as well as escape of tumors from immune surveillance. The PD-1/PD-L1 axis has been extensively exploited and has made huge impact on cancer therapy.   PD-1 Fc fusion proteins (P099F and P099G) interact with PD-L1 (P101F and P101G) and contain the binding epitope for Pembrolizumab (Keytruda) - Merck’s anti-PD-1 antibody.

Interacting protein(s): PD-L1 (P7101FP7101G), PD-L2 (P7103FP7103G)
Related products: Checkpoint Proteins

For orders over 1 mg please inquire here.

Quick Spec

Species: Human
Catalog No.: P7099F
Synonym: CD279, PDCD1, (programmed cell death 1), hPD-1, hPD-l, PD1, SLEB2
Tag: mouse IgG2a-Fc
GenBank Accession: NM_005018.2
SwissPro Accession: Q15116
Construction: h.PD-1 (N33-T145)-m.IgG-Fc
Expression Host: 293T
Mol. Wt. (Calculated): 39,706 daltons
Mol. Wt. (SDS-PAGE): 42 Kd
Abs 0.1% (= 1 mg/ml): 1.046
Purity: 95 %

Description

PD-1 was identified in apoptosis induced cells by subtractive hybridization. Like other CD28, CTLA-4 and ICOS, it is a membrane anchored IgSF family member and like CTLA-4, it contains a single IgV excellular domain and an ITIM (immune receptor tyrosine based inhibition motif)-containing intracellular region. PD-1 lacks the MYPPPY motif that is required for binding of B7-1 and B7-2(CD86), instead it binds to two ligands, PDL1 and PDL2. Also, similar to CTLA-4, engagement of PD-1 with its ligand triggers inhibitory signaling, diminish cell proliferation and cytokine production.

PD-1 deficiency, similar to CTLA-4 deficiency, results in lymphoproliferative disorders including splenomegaly, B cell expansion, with elevated serum antibody levels, lupus glomerulonephritis, arthritis, and autoimmune cardiomyopathy. Thus, after T cell activation, PD-1 and CTLA-4 are upregulated in order to contain the T cell response. Both molecules appears to be critical for maintenance of tolerance, though PD-1 appears to be more important for the peripheral than central tolerance.

On the non-professional antigen presenting parenchymal cells (do not express B7-1 and B7-1), the expression of PD-1 ligands and the B7-H2 (ICOS ligand) underlying the counter-balance nature of the PD-1 and ICOS pathways.

Amino Acid Sequence

References

  1. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Shinohara T., Taniwaki M., Ishida Y., Kawaich M., Honjo T. Genomics 23:704-706 (1994)
  2. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Fife B.T., Pauken K.E. Ann. N. Y. Acad. Sci. 1217:45-59 (2011)
  3. Role of the PD-1 pathway in the immune response. Riella L.V., Paterson A.M., Sharpe A.H., Chandraker A. Am. J. Transplant. 12:2575-87 (2012)